Tagraxofusp
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Using the evidence pack as given — note the pack's own repurposing_rationale for the top-ranked prediction (rank 1, esotropia) explicitly flags it as a likely embedding false-positive, and this is reflected faithfully below rather than dressed up.
Tagraxofusp: From Blastic Plasmacytoid Dendritic Cell Neoplasm to Esotropia
One-Sentence Summary
Tagraxofusp is a CD123 (IL-3Rα)-targeted diphtheria toxin fusion protein, referenced in this evidence pack's own trial data as approved for blastic plasmacytoid dendritic cell neoplasm (BPDCN). The TxGNN model's top-ranked prediction is Esotropia, but this association is currently supported by 0 clinical trials and 0 publications, and the model's own rationale describes it as a probable false positive arising from sparse-data embedding rather than a biologically grounded signal.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not captured in structured regulatory data (Finland). Referenced only via trial background text as BPDCN. |
| Predicted New Indication | Esotropia |
| TxGNN Prediction Score | 99.73% |
| Evidence Level | L5 |
| Finland Market Status | Not marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism-of-action data is not available for tagraxofusp in this evidence pack (flagged as a High-severity data gap, DG002). Based on information embedded in the associated clinical trial records, tagraxofusp is a protein-drug conjugate combining a truncated diphtheria toxin with IL-3, redirected to kill CD123-expressing cells — the mechanism underlying its approval for BPDCN and its investigational use in CD123-positive AML/MDS.
Esotropia is a neuromuscular/structural disorder of ocular alignment involving the extraocular muscles and their innervation; it has no known association with CD123 expression or cytotoxic protein-toxin biology. There is no mechanistic pathway connecting tagraxofusp's cytotoxic, hematologic-malignancy-targeted action to this ophthalmologic condition.
Consistent with this, the evidence pack's own rationale for this candidate states there is "no mechanistic relationship" and attributes the score to a TxGNN embedding artifact under sparse data ("屬TxGNN在稀疏資料下的嵌入假陽性"). No clinical trials, registry entries, or publications were found linking the two, which is itself evidence against — not for — the prediction.
Clinical Trial Evidence
Currently no related clinical trials registered
Literature Evidence
Currently no related literature available
Finland Market Information
Tagraxofusp is not currently marketed in Finland — 0 authorizations on file, no license records available.
Cytotoxicity
| Item | Content |
|---|---|
| Cytotoxicity Classification | Targeted therapy (CD123-directed cytotoxic fusion protein: truncated diphtheria toxin + IL-3) |
| Myelosuppression Risk | Please refer to the package insert warnings and precautions |
| Emetogenicity Classification | Please refer to the package insert warnings and precautions |
| Monitoring Items | Please refer to the package insert warnings and precautions |
| Handling Protection | Please refer to the package insert warnings and precautions |
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The TxGNN score is numerically high, but zero clinical trials and zero publications support a tagraxofusp–esotropia link, and the model's own mechanistic rationale identifies this as a likely false positive with no biological plausibility. There is no basis to advance this candidate.
To proceed, the following is needed:
- TFDA package insert warnings/contraindications (Blocking gap, DG001) — required before any S1 safety review regardless of indication
- Confirmed mechanism-of-action data (DG002)
- Independent biological or pharmacological rationale for a CD123-targeted cytotoxic agent in esotropia, if this candidate is to be pursued further
- Consider redirecting evaluation effort to rank 2 ("pre-malignant neoplasm"), which carries stronger supporting evidence (L3, 5 clinical trials, decision stage S1) within the same evidence pack
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.